Skip to main content
. 2019 Mar 29;9:5348. doi: 10.1038/s41598-019-41866-y

Figure 6.

Figure 6

NPsFA-A1411/DOX/a221 nanoparticles sensitize leukemia cells that are resistant to chemotherapy. (A) CCK-8 assays measuring proliferation of K562DR or (BD) three primary cells derived from AML patients experiencing chemoresistant relapse and treated with the indicated nanoparticles for 24 hours, followed by incubation with different doses of doxorubicin for an extra 48 hours. Data represent 3 independent experiments, each conducted in triplicate.